Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 21 2024
0mins
Source: Newsfilter
Presentation at ACAAI Annual Meeting: Astria Therapeutics will have leading experts present two posters on quality of life data related to hereditary angioedema (HAE) at the ACAAI Annual Scientific Meeting in Boston on October 25, 2024.
Company Overview: Astria Therapeutics focuses on developing therapies for allergic and immunologic diseases, with its lead program navenibart (STAR-0215) currently in clinical trials for HAE treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
